We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Yourgene Health Plc | LSE:YGEN | London | Ordinary Share | GB00BN31ZD89 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.515 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMYGEN
RNS Number : 9094R
Yourgene Health PLC
11 July 2022
Yourgene Health plc
("Yourgene" or the "Company")
Notice of Final Results
Investor meeting
Manchester, UK - 11 July 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that its audited final results for the year ended 31 March 2022 will be issued on Wednesday 27 July 2022.
Investor briefing
Lyn Rees, Chief Executive Officer and Barry Hextall, Chief Financial Officer, will provide a live presentation relating to the Company's final results for the year ended 31 March 2022 via the Investor Meet Company platform on Wednesday 27 July 2022 at 4:30pm BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet Yourgene Health plc via:
https://www.investormeetcompany.com/yourgene-health-plc/register-investor
Investors who already follow Yourgene Health plc on the Investor Meet Company platform will automatically be invited.
Yourgene Health plc Tel: +44 (0)161 669 8122 Lyn Rees, Chief Executive Officer investors@yourgene-health.com Barry Hextall, Chief Financial Officer Joanne Cross, Director of Marketing Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880 Liam Murray / James Caithie / Ludovico Lazzaretti Singer Capital Markets (Joint Corporate Tel: +44 (0)20 7496 3000 Broker) Aubrey Powell / Tom Salvesen / George Tzimas Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600 Corporate Broker) Nicholas Moore / Matthew Blawat / Ben Maddison Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com Relations) Paul McManus / Lianne Applegarth Mob: 07980 541 893 / Mob: 07584 391 303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NORBKFBPPBKDFOK
(END) Dow Jones Newswires
July 11, 2022 02:00 ET (06:00 GMT)
1 Year Yourgene Health Chart |
1 Month Yourgene Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions